I am quite positive, currently seem to be fortunate one as have purchased a lot of shares over last two months.
My reasons are:
1) Gastric cancer is the third leading cause of cancer mortality. PAT-SC1 which has been used to treat positive gastric cancer patients in clinical trials.
2) China is one of the countries with the highest incidence of gastric cancer. Over 40% of all new gastric cancers in the world.
3) GlobalData estimates drug sales for Gastric and Gastroesophageal Junction Adenocarcinome (G/GEJAC) to be US$1.13bn in 2014 to raise to US$4.39bn in 2024
4) PAB cash on hand is approx $4m
5) joint venture with Chinese biotech (Hefei Co-source Biomedical Co LTD). China desperate to be self sufficient with pharmaceuticals and healthcare.
6) CEO has focused company on PAT-SC1, when cash starts flowing in the door they will go back to commercialising the rest of Patrys pipeline.
On negative: still very unsure why selling at 0.9 cents
